MedPath

AstraZeneca

AstraZeneca logo
🇬🇧United Kingdom
Ownership
Public
Employees
89.9K
Market Cap
$270.3B
Website
http://www.astrazeneca.co.uk
Introduction

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

astrazeneca.com
·

Datopotamab deruxtecan Biologics License Application accepted in the US for treating advanced nonsquamous NSCLC

AstraZeneca and Daiichi Sankyo's BLA for datopotamab deruxtecan (Dato-DXd) was accepted in the US for treating advanced nonsquamous NSCLC post-systemic therapy, based on TROPION-Lung01 Phase III trial results showing improved PFS over docetaxel. FDA decision expected Q4 2024. Ongoing trials aim to establish Dato-DXd as a new standard in NSCLC treatment.
bloomberg.com
·

Largest Covid Vaccine Study Yet Finds Links to Health Conditions

Global vaccine safety study links COVID-19 vaccines to small increases in rare neurological, blood, and heart-related conditions, including heart inflammation from mRNA vaccines and brain blood clots from viral-vector vaccines.
mdpi.com
·

Revolutionizing Drug Discovery: A Comprehensive Review

AI and ML revolutionize drug discovery by enhancing efficiency, reducing costs, and accelerating timelines. They aid in drug-target identification, molecular properties analysis, compound screening, and toxicity assessment, offering a promising strategy to overcome pharmaceutical industry challenges.
prnewswire.com
·

Global Market Pipeline for Vaccine Technologies 2024-2028

The report highlights advancements in vaccine technologies targeting infectious diseases, cancers, and allergies, emphasizing market growth driven by R&D, new product launches, and strategic collaborations. It covers market segmentation, trends, and competitive landscape, offering insights for stakeholders and potential entrants.
imfinzihcp.com
·

IMFINZI® (durvalumab) Immunotherapy for Cancer

IMFINZI® (durvalumab) and IMJUDO® (tremelimumab-actl) can cause severe or fatal immune-mediated adverse reactions across various organ systems. Monitoring and prompt management are crucial. Indications include treatment for specific types of lung, biliary tract, and endometrial cancers. Adverse reactions range from pneumonitis, colitis, hepatitis, to endocrinopathies, with varying incidences based on treatment combinations.
finance.yahoo.com
·

Immuno-oncology Clinical Trials Market Poised for Remarkable Growth

The Global Immuno-oncology Clinical Trials Market is projected to grow from USD 6.13 billion in 2023 to USD 12.87 billion by 2030, at a CAGR of 11.17%. The report analyzes market dynamics, competitive landscape, and profiles key vendors like AstraZeneca and BioNTech. It covers market segmentation by design, phase, indication, and regional prospects including North America, Asia-Pacific, and EMEA.

What is Disease X? Know all about this 'fatal than Covid-19' crisis that global leaders are brainstorming at Davos 2024

The World Economic Forum's Davos meeting focuses on 'Disease X', a potential future pandemic pathogen, emphasizing global readiness. Experts, including WHO's Tedros Adhanom Ghebreyesus, discuss preparation strategies. Disease X represents unknown infectious threats, highlighting the need for research, surveillance, and international collaboration to safeguard public health.
curavit.io
·

PharmaVoice's Crystal Ball: What's next in drug innovation

Pharma's 2024 outlook highlights advancements in gene and cell therapies, AI in drug development, and patient-centric R&D. Innovations like CRISPR, mRNA vaccines, and treatments for obesity, aging, and tough-to-treat cancers are set to transform healthcare. Regulatory shifts and DEI in clinical trials aim for more inclusive and efficient drug development.
aol.com
·

JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss industry

The obesity drug market, led by GLP-1 treatments like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, is booming with a projected $100 billion value by 2030. Companies are innovating with new dosages, delivery methods, and exploring additional health benefits. Competition is fierce, with firms like Pfizer and Roche entering the market, while others like Sanofi stay out. The focus is on expanding treatment options and proving efficacy in serious diseases.
pharmavoice.com
·

PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trends

The article highlights 2024 trends in drug innovation, including advancements in gene and cell therapies, AI in drug discovery, and the rise of patient-centric R&D. It also covers the evolution of clinical trials towards decentralization and inclusivity, emphasizing the importance of technology and patient voices in shaping future treatments.
© Copyright 2025. All Rights Reserved by MedPath